TheraRadar

Corcept

Pre-Approval PRO BETA
59
Total Trials
8
Phase 3
13
Phase 2
9
Recruiting
369
Score

Pipeline by Phase

Phase 3
8
Phase 2
13
Phase 1
40

Therapeutic Focus

Healthy Nonalcoholic Steatohepatitis (NASH) Cushing Syndrome Healthy Adults Cushing's Syndrome

Clinical Trials (59)

NCT04308590 Phase 3 COMPLETED

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Started: 7/27/2020

NCT03697109 Phase 3 COMPLETED

A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome

Started: 11/15/2018

NCT05257408 Phase 3 ACTIVE NOT RECRUITING

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Started: 6/29/2022

NCT04329949 Phase 3 TERMINATED

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Started: 6/30/2020

NCT00637494 Phase 3 TERMINATED

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

Started: 3/1/2008

NCT01925092 Phase 3 WITHDRAWN

Mifepristone in Children With Refractory Cushing's Disease

Started: 8/1/2013

NCT00936741 Phase 3 COMPLETED

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

Started: 7/1/2009

NCT01371565 Phase 3 COMPLETED

Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Started: 11/1/2010

NCT07259317 Phase 2 RECRUITING

Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

Started: 1/27/2026

NCT06906341 Phase 2 RECRUITING

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Started: 4/11/2025

NCT05407324 Phase 2 RECRUITING

Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

Started: 11/15/2022

NCT06108219 Phase 2 ACTIVE NOT RECRUITING

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Started: 10/25/2023

NCT03604198 Phase 2 ACTIVE NOT RECRUITING

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Started: 5/7/2018

NCT03776812 Phase 2 COMPLETED

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Started: 4/5/2019

NCT03818256 Phase 2 COMPLETED

A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications

Started: 12/4/2019

NCT04524403 Phase 2 COMPLETED

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Started: 9/9/2020

NCT03823703 Phase 2 TERMINATED

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH)

Started: 11/4/2020

NCT02804750 Phase 2 COMPLETED

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Started: 6/1/2016

NCT07553663 Phase 1 RECRUITING

Evaluating the Pharmacokinetics and Safety of Miricorilant

Started: 4/30/2026

NCT07276373 Phase 1 RECRUITING

Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies

Started: 1/16/2026

NCT06947304 Phase 1 RECRUITING

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Started: 8/22/2025

NCT07240116 Phase 1 COMPLETED

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

Started: 9/11/2025

NCT06495944 Phase 1 COMPLETED

Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

Started: 5/31/2024

NCT06928779 Phase 1 COMPLETED

Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

Started: 10/8/2024

NCT05553470 Phase 1 COMPLETED

Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant

Started: 3/3/2022

NCT05117489 Phase 1 COMPLETED

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

Started: 11/23/2021

NCT04373265 Phase 1 COMPLETED

Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)

Started: 9/30/2020

NCT06094790 Phase 1 COMPLETED

A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects

Started: 5/18/2017

NCT06094712 Phase 1 COMPLETED

A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects

Started: 4/7/2016

NCT06094725 Phase 1 COMPLETED

A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant

Started: 1/6/2020

NCT06094738 Phase 1 COMPLETED

A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects

Started: 9/19/2020

NCT03437941 Phase 1 TERMINATED

Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Started: 2/20/2018

NCT05712265 Phase 1 COMPLETED

Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

Started: 1/24/2023

NCT05003713 Phase 1 COMPLETED

Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants

Started: 8/3/2021

NCT05347979 Phase 1 COMPLETED

Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants

Started: 5/25/2022

NCT02762981 Phase 1 COMPLETED

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

Started: 5/23/2016

NCT04672512 Phase 1 COMPLETED

Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants

Started: 10/23/2020

NCT00698022 Phase 1 COMPLETED

A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers

Started: 11/1/2008

NCT04249323 Phase 1 COMPLETED

Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

Started: 1/27/2020

NCT04990310 Phase 1 COMPLETED

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

Started: 8/18/2021

NCT04994743 Phase 1 COMPLETED

Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

Started: 7/13/2021

NCT04795479 Phase 1 COMPLETED

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

Started: 1/22/2021

NCT04672499 Phase 1 COMPLETED

Single and Multiple Dose Study of Miricorilant (CORT118335) Tablet Formulations in Healthy Participants

Started: 4/27/2020

NCT03877562 Phase 1 COMPLETED

The Effect of CORT118335 on Olanzapine-Induced Weight Gain

Started: 4/1/2019

NCT03512548 Phase 1 COMPLETED

Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites

Started: 4/10/2018

NCT03067376 Phase 1 COMPLETED

A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body

Started: 8/1/2016

NCT03508635 Phase 1 COMPLETED

CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Started: 9/1/2014

NCT03878264 Phase 1 COMPLETED

Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants

Started: 8/6/2018

NCT03315338 Phase 1 COMPLETED

First-in-human Study in Healthy Subjects

Started: 9/15/2017

NCT03877952 Phase 1 COMPLETED

Mass Balance Recovery and Metabolite Profile of CORT125281 in Healthy Male Participants

Started: 9/13/2018

NCT03540836 Phase 1 COMPLETED

A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants

Started: 5/24/2018

NCT03335956 Phase 1 COMPLETED

CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)

Started: 9/21/2017

NCT03457597 Phase 1 COMPLETED

Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

Started: 3/6/2018

NCT03442621 Phase 1 COMPLETED

Relacorilant Food Effect Study in Healthy Subjects

Started: 1/16/2018

NCT03258372 Phase 1 COMPLETED

Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites

Started: 8/16/2017

NCT03259542 Phase 1 COMPLETED

Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Started: 8/9/2017

NCT02014337 Phase 1 COMPLETED

Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors

Started: 1/1/2014

NCT00752843 Phase 1 COMPLETED

A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers

Started: 9/1/2008

NCT05772169 Phase 4 COMPLETED

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

Started: 3/31/2023

Drug Candidates

Miricorilant (Cohort A) Miricorilant (Cohort B) Miricorilant Relacorilant relacorilant Relacorilant 150 mg once daily (QD) Miricorilant Treatment A Miricorilant Treatment B Miricorilant Treatment C Miricorilant Treatment D
Activity Status: Active
Last Trial Started: 4/30/2026
Last Trial Ended: 3/3/2026
Trials (12 months): 5
Completed Trials: 45
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.